News >

Rugo Covers Scope of Recent Breast Cancer Advances

Chelsea LoCascio
Published: Tuesday, Dec 05, 2017

Hope Rugo, MD

Hope Rugo, MD
Reversing hormone resistance for estrogen receptor (ER)-positive breast cancer and introducing new targeted therapies for patients with triple-negative breast cancer (TNBC) are vital points of discussion in the community, according to Hope S. Rugo, MD.

In an interview during the meeting, Rugo, a professor of medicine and director of Breast Oncology and Clinical Trials Education at the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco, discussed a variety of agents for the treatment of patients with ER-positive breast cancer, such as mTOR inhibitors, PI3K inhibitors, and CDK4/6 inhibitors, in addition to novel targeted therapies being investigated in TNBC.

OncLive: Can you give an overview of your presentation?

Rugo: We had a great program [at the] 2017 State of the Science SummitTM on Breast Cancer…we had a number of different talks that really covered the different biologic subtypes of breast cancer from our clinical faculty.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication